ROG earnings call summary

Prepared Highlights

• Q2 2025 total sales increased 6.5% quarter-on-quarter, led by industrial, portable electronics, A&D, and ADAS end markets (CEO, prepared).
• AES segment revenues up 4.6% quarter-on-quarter; EMS segment revenues up 8.2% quarter-on-quarter (CFO, prepared).
• Q2 GAAP net loss of $73.6 million ($4.00 per share), including $4.3 million restructuring costs and a $71.8 million non-cash goodwill/intangibles impairment for curamik (CFO, prepared).
• Q2 adjusted EPS of $0.34, up from $0.27 in Q1 (CFO, prepared).
• Q2 gross margin 31.6%, up 170 bps from Q1; adjusted EBITDA $23.9 million (11.8% of sales) (CFO, prepared).
• Q2 cash balance $157 million, down $18.4 million from Q1; CapEx $8.1 million; share repurchases $28.1 million (CFO, prepared).
• Full-year run-rate savings from curamik European restructuring actions projected >$13 million, incremental to the $32 million annual run-rate savings previously communicated (CFO, prepared).
• Total restructuring costs for curamik European operations estimated at $12 million–$20 million, incurred Q3 2025 to Q3 2026 (CFO, prepared).
• Approximately $76 million remaining on existing share repurchase program (CFO, prepared).
• Q2 industrial markets grew at a double-digit rate quarter-on-quarter; portable electronics also grew at a double-digit rate (CFO, prepared).
• ADAS sales increased for the third consecutive quarter; A&D sales higher in both segments (CFO, prepared).

Official Guidance (Q3 2025):

• Revenue: $200 million–$215 million (midpoint ~2% sequential increase) (CFO, prepared).
• Gross margin: 31.5%–33.5% (midpoint ~90 bps improvement) (CFO, prepared).
• Adjusted EPS: $0.50–$0.90; GAAP EPS: breakeven to $0.40 (CFO, prepared).
• Full-year tax rate projected at ~30% (CFO, prepared).

Mgmt Quotes:

• “The recent leadership transition does not signal a major change in strategy or a deterioration of our competitive advantages. Rather, the changes are needed to increase the speed of execution, improve accountability and create a more dynamic organization to accelerate growth and improve margins.” (CEO)
• “With lower growth in the EV market outside of China, it is necessary that we have a cost competitive footprint in each region. Our plans include ramping up manufacturing capabilities in China and reducing capacity in our European operations.” (CEO)
• “The full year run rate savings from these actions are projected to be in excess of $13 million.” (CEO)
• “We are guiding gross margin to be in the range of 31.5% to 33.5% or a 90-basis point improvement at the midpoint of our range.” (CFO)
• “Based on our current view, we anticipate share repurchases in Q3 to be in a similar range to the second quarter.” (CFO)

Prepared Metrics

Q&A Batch (1-2 of 2)

Q1 — Daniel Joseph Moore

• Topic: Strategic priorities, organic growth timeline, and gross margin targets
• Key points:
  • Cost initiatives include $13 million restructuring targeted cost savings; organizational changes aim to reduce lead times and improve responsiveness.
  • Management identified short-, mid-, and long-term top-line opportunities, with near-term focus on short and mid-term to impact revenue.
  • No year-over-year organic growth timeline given beyond next quarter’s guidance; company policy prohibits forecasting beyond that.
  • Margin expansion depends on top-line growth to utilize existing capacity; additional restructuring savings will also support margin optimization.
• Mgmt stance: Neutral — no specific growth or margin targets provided; guidance limited to next quarter.

Q2 — Craig Andrew Ellis

• Topic: Speed of execution improvements and cumulative cost savings
• Key points:
  • Lead times in some product lines targeted for reduction by 50% to 60% to meet customer demand (e.g., delivery within 1 day vs. 3–4 days).
  • New product launches planned over coming quarters; R&D focus to accelerate prototype delivery and program wins.
  • Cumulative cost savings: $32 million (from prior plan) plus incremental $13 million (curamik restructuring) = $45 million total.
  • Incremental $13 million annual savings expected to crystallize in P&L likely in Q4 2026, not fully in full-year 2026.
• Mgmt stance: Neutral — execution improvements outlined but no quantified timeline for lead-time reduction; cost savings timing delayed to late 2026.